Clinical significance of CD38 expression in chronic lymphocytic leukemia (original) (raw)

Immunoglobulin VH Genes and CD38 Expression Analysis in B-Cell Chronic Lymphocytic Leukemia

Acta Haematologica, 2006

a more stringent cutoff of 7% provided the best separation for different prognostic groups [7]. Since both the IgV H mutational status and CD38 expression have been proposed as strong independent prognostic markers of outcome [5] , in the current study, the V H mutation status and CD38 expression were analyzed in 52 B-CLL patients at diagnosis to clarify their correlation. Clinical diagnosis of B-CLL was based on standard morphologic and immunophenotypic criteria (CD19+/ CD5+, CD19+/CD23+, weak sIg+). The median age at diagnosis was 64 years; the male/female ratio was 1.7, and the clinical risk category in most cases was Rai stage O or I. Gene analysis and immunophenotypic analysis were performed on peripheral blood samples. IgV H mutation status was evaluated by polymerase chain reaction using a consensus 5 FR1 region primer together with a consensus 3 JH region primer. PCR products were sequenced using the BigDye Terminator Cycle Sequencing Reaction kit (Applied Biosystems) and analyzed with an automated DNA sequencer (ABI Prism 310). Nucleotide sequences were aligned with those in the BlastN database. Unmutated immunoglobulin sequences were defi ned as sequences with 2% or less deviation from any germ line IgV H sequence. The V H family gene utilized in the 52 pa

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

Blood, 2001

CD38 is a transmembrane glycoprotein expressed on the surface of leukemic cells in a significant percentage of patients with B-cell chronic lymphocytic leukemia (B-CLL). A recent study suggested that CD38 expression has prognostic value in CLL. Peripheral blood samples from 218 patients with B-CLL were analyzed by flow cytometry for CD38 expression on CD5/19+ leukemic cells. Various patient characteristics were studied including age, sex, Rai and Binet stages, splenomegaly, hepatomegaly, hemoglobin (Hgb) level, β-2 microglobulin (β2M) level in the serum, number of nodal sites involved with disease, and length of survival. The Kaplan-Meier method was used to construct survival curves, and the log-rank statistic was used to compare these curves. CD38 was expressed in 20% or more of leukemic cells in 43% of the patients. Patients with high CD38 expression (20% or more) had significantly shorter survival times (P =.00005). Multivariate analyses showed that CD38 expression is an importan...

STUDY OF THE IMMUNOLOGICAL MARKERS CD49d AND CD38 IN EARLY-STAGE B-CLL PATIENTS

Journal of IMAB - Annual Proceeding (Scientific Papers), 2018

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-lymphocytes into the blood stream, primary and secondary lymphoid organs as a consequence of defect in the apoptosis. Most frequently it affects people aged 67-72. The greater part of CLL patients are in the early stage of the disease at the time of diagnosis, which gives a chance to delay the therapy. In 2008 the diagnostic criteria for CLL were revised. New prognostic and predictive factors were added in order to make the indications for starting the treatment more precise The aims of our study were: to determine the frequency of monoclonal B-cell lymphocytosis (MBL) in the subjects with absolute lymphocytosis, to establish a relationship between the flow cytometric markers CD49d and CD38 in patients with early stages Rai O-II / Binet A. To distinguish the patients with B-CLL from MBL as well as to define the expression of immunological markers we used flow cytometric analysis of peripheral blood. The results of our study have shown that a small number of patients met the criteria for MBL. Flow cytometric markers CD49d and CD38 associated with unfavorable prognosis were negative in most of the early stage patients.

B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2009

Background Otherwise healthy persons with a small number of B-cell clones circulating in the peripheral blood have been designated as having monoclonal B-cell lymphocytosis (MBL). Hospital-based series indicate an excess risk of progression from MBL to chronic lymphocytic leukemia (CLL). In this prospective cohort study, we tested the hypothesis that CLL is always preceded by MBL. Methods Among 77,469 healthy adults who were enrolled in the nationwide, population-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, we identified 45 subjects in whom CLL was subsequently diagnosed (up to 6.4 years later) through the collection of a peripheral-blood sample. Using six-color flow cytometry (with antibodies CD45, CD19, CD5, CD10, kappa, and lambda) and immunoglobulin heavychain gene rearrangement by reverse-transcriptase-polymerase-chain-reaction assay, we determined the association between MBL and subsequent CLL and characterized the immunoglobulin gene repertoire of the prediagnostic B-cell clones. Results On the basis of either flow-cytometric or molecular analysis, 44 of 45 patients with CLL (98%; 95% confidence interval [CI], 88 to 100) had a prediagnostic B-cell clone; in 41 patients (91%; 95% CI, 79 to 98), the presence of the B-cell clone was confirmed by both methods. The presence of immunoglobulin heavy-chain variable (IGHV) genes was determined in 35 of 45 prediagnostic clones (78%). Of these clones, 16 (46%) were IGHV3 subgroup genes (including 6 [17%] IGHV3-23 genes) and 9 (26%) were IGHV4 subgroup genes (including 4 [11%] IGHV4-34 genes). Furthermore, 27 of 35 of the IGHV sequences (77%) had mutations, with similar distributions after stratification either below or above the median time between the collection of the prediagnostic blood sample and the subsequent CLL diagnosis. Conclusions In peripheral blood obtained up to 77 months before a CLL diagnosis, prediagnostic B-cell clones were present in 44 of 45 patients with CLL.